论文部分内容阅读
氟桂利嗪(Flunarizin)在联邦德国是最常用的血流促进剂,其适应症是缺血所致的神经障碍(头晕、美尼埃尔氏病、眼球震颤、耳鸣、不安以及缺血所致的失眠、恶心、呕吐)和外周动脉血流障碍。本品是三氟拉嗪衍生物,在推荐剂量范围内对钙生理性流入心肌细胞无影响。其副作用众所周知,治疗之始出现疲乏,继续治疗时出现失眠、推动力缺乏、衰弱感、头痛、口干、恶心、胃肠道障碍和体重增加。
Flunarizin is the most commonly used blood flow promoter in the Federal Republic of Germany and its indication is ischemia-induced neurological disorders (dizziness, Meniere’s disease, nystagmus, tinnitus, anxiety and ischemia Induced insomnia, nausea, vomiting) and peripheral arterial blood flow disorders. This product is trifluoperazine derivatives, in the recommended dose range of calcium influx into myocardial cells without impact. The side effects are well-known, the beginning of treatment appeared tired, continue treatment of insomnia, lack of driving force, weakness, headache, dry mouth, nausea, gastrointestinal disorders and weight gain.